Timolol Maleate

ROCHESTER, Minn., March 25, 2026 /PRNewswire/ -- Nanodropper today announced results from a randomized clinical trial demonstrating that microvolume eyedrop delivery using the Nanodropper adaptor achieved greater intraocular pressure reduction, fewer adverse effects, and significantly reduced premature bottle exhaustion compared with conventional eyedrops in patients with glaucoma or ocular hypertension. Continue Reading The study, "Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial," was published in the Journal of Cataract & Refractive Surgery and evaluated real-world use of microdrops delivered via the Nanodropper Adaptor compared to conventional drops. Study: Nanodropper reduces bottle waste by 80% and improves pressure control in glaucoma vs standard drops. Post this Key Study Findings In the prospective, examiner-masked, randomized crossover trial, adults with stable primary open-angle glaucoma or ocular hypertension using either latanoprost 0.005% or timolol maleate 0.5% monotherapy self-administered conventional drops or Nanodropper microdrops for 12 weeks before switching treatments. Results showed clear advantages for microvolume delivery: Superior intraocular pressure (IOP) reduction: Microdrops: 1.6 mm Hg reduction from baseline Conventional drops: 0.13 mm Hg reduction 80% reduction in premature bottle exhaustion: 83% of patients ran out of drops early with conventional bottles Only 17% experienced early exhaustion using Nanodropper Fewer reported side effects: 83% of patients reported adverse effects with conventional drops 62% reported adverse effects with microdrops Most study participants also reported that the Nanodropper device was easy to administer and helped prevent medication waste. Addressing a Major Challenge in Glaucoma Treatment Although the eye can retain only 7–10 microliters of fluid, conventional eyedrops typically deliver 25–60 microliters per drop, resulting in overflow, wasted medication, and increased systemic exposure. By reducing drop volume, the Nanodropper adaptor increases the number of usable doses per bottle and may help patients avoid interruptions in therapy caused by running out of medication early. Study authors concluded that microdrop delivery using the Nanodropper adaptor improved intraocular pressure reduction while decreasing premature bottle exhaustion and non-systemic adverse effects, suggesting the technology may enhance medication adherence and long-term glaucoma management. "These findings are very encouraging, adding to the growing body of evidence that supports the use of microdrops for instillation of a wide variety of eyedrop medications, including in the at-home setting," said Dr. Eric Grewal, Medical Director of Nanodropper and a key author on the study. "The additional reduction in IOP achieved with the Nanodropper for subjects already on standard treatment suggests that microdrops could maximize pressure control from existing regimens, potentially delivering extra therapeutic benefit even without medication changes or escalation of therapy." "We are pleased to see the Nanodropper validated as a low-cost solution for delivering IOP-lowering medications and defraying premature bottle exhaustion," adds Dr. Allisa Song, Chief Executive Officer of Nanodropper. "Every bit of pressure control matters for patients with glaucoma and ocular hypertension." The full journal article can be viewed using the following link: About Nanodropper Nanodropper develops precision microvolume delivery technology designed to reduce eyedrop size, minimize medication waste, and improve patient usability in ophthalmic treatments. Nanodroppers are available for patients, clinics and doctors to purchase at Nanodropper.com Media Contact: Ariana Rodriguez Marketing Manager [email protected] SOURCE Nanodropper 21% more press release views with Request a Demo

New Delhi: Drug firm FDC Ltd is recalling over 60,000 bottles of a generic medication, used to treat glaucoma, in the US market due to manufacturing issue, according to the US health regulator. As per the latest Enforcement Report by Food and Drug Administration (USFDA), the Mumbai-headquartered drug firm is recalling 60,428 bottles of Timolol Maleate Ophthalmic Solution in the US market. The company is recalling the affected lot due to "Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle," the USFDA said. The drugmaker initiated the Class II nationwide (US) recall on April 18 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Shares of FDC on Friday ended 0.31 per cent up at Rs 430 apiece on the BSE.